33 Citations (Scopus)

Abstract

Patching small intestinal defects with colon serosa results in the growth of functional neomucosa. However, the rate of neomucosal growth is slow and the defect contracts markedly. The aim of this study was to determine if systemic urogastrone would enhance neomucosal growth. Twenty-two New Zealand white rabbits had two 2 × 5-cm ileal defects patched with colon serosa and osmotic pumps placed subcutaneously. Eleven animals had saline infused at a rate of 5 μl/hr. The other eleven rabbits had urogastrone (1 mg/ml saline) infused at the same rate. One animal died in this group. There was a modest increase in neomucosal growth after 2 weeks of urogastrone infusion. Three weeks after patching, defect coverage was significantly greater in the urogastrone group (99.8 ± 0.1 vs 96.0 ± 1.2%, P < 0.005) and more defects were completely covered by neomucosa ( 6 10 vs 1 12, P < 0.05). Less contraction occurred in the urogastrone group (46 ± 2 vs 35 ± 3% initial defect, P < 0.005) and resultant neomucosal surface area was greater (361 ± 12 vs 266 ± 20 mm2, P < 0.0005). In vitro glucose uptake was significantly greater in the urogastrone group but disaccharidase and diamine oxidase activity were similar. Crypt cell production rate was significantly greater 2 weeks after operation compared to 3 weeks in both groups and was greater in the urogastrone group compared to the saline group at 2 weeks (24.9 ± 1.1 vs 20.1 ± 1.1, P < 0.02). Systemic urogastrone enhances neomucosal growth by increasing the rate of growth and diminishing contraction. A marked proliferative response is associated with intestinal patching prior to 21 days and is increased by systemic urogastrone.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalJournal of Surgical Research
Volume42
Issue number4
DOIs
StatePublished - Jan 1 1987

Fingerprint

Epidermal Growth Factor
Growth
Serous Membrane
Colon
Disaccharidases
Rabbits
Amine Oxidase (Copper-Containing)
Glucose

ASJC Scopus subject areas

  • Surgery

Cite this

Stimulation of neomucosal growth by systemic urogastrone. / Thompson, Jon S; Sharp, John G; Saxena, S. K.; McCullagh, K. G.

In: Journal of Surgical Research, Vol. 42, No. 4, 01.01.1987, p. 402-410.

Research output: Contribution to journalArticle

Thompson, Jon S ; Sharp, John G ; Saxena, S. K. ; McCullagh, K. G. / Stimulation of neomucosal growth by systemic urogastrone. In: Journal of Surgical Research. 1987 ; Vol. 42, No. 4. pp. 402-410.
@article{84915c552d534ae99967e4645d0cdeba,
title = "Stimulation of neomucosal growth by systemic urogastrone",
abstract = "Patching small intestinal defects with colon serosa results in the growth of functional neomucosa. However, the rate of neomucosal growth is slow and the defect contracts markedly. The aim of this study was to determine if systemic urogastrone would enhance neomucosal growth. Twenty-two New Zealand white rabbits had two 2 × 5-cm ileal defects patched with colon serosa and osmotic pumps placed subcutaneously. Eleven animals had saline infused at a rate of 5 μl/hr. The other eleven rabbits had urogastrone (1 mg/ml saline) infused at the same rate. One animal died in this group. There was a modest increase in neomucosal growth after 2 weeks of urogastrone infusion. Three weeks after patching, defect coverage was significantly greater in the urogastrone group (99.8 ± 0.1 vs 96.0 ± 1.2{\%}, P < 0.005) and more defects were completely covered by neomucosa ( 6 10 vs 1 12, P < 0.05). Less contraction occurred in the urogastrone group (46 ± 2 vs 35 ± 3{\%} initial defect, P < 0.005) and resultant neomucosal surface area was greater (361 ± 12 vs 266 ± 20 mm2, P < 0.0005). In vitro glucose uptake was significantly greater in the urogastrone group but disaccharidase and diamine oxidase activity were similar. Crypt cell production rate was significantly greater 2 weeks after operation compared to 3 weeks in both groups and was greater in the urogastrone group compared to the saline group at 2 weeks (24.9 ± 1.1 vs 20.1 ± 1.1, P < 0.02). Systemic urogastrone enhances neomucosal growth by increasing the rate of growth and diminishing contraction. A marked proliferative response is associated with intestinal patching prior to 21 days and is increased by systemic urogastrone.",
author = "Thompson, {Jon S} and Sharp, {John G} and Saxena, {S. K.} and McCullagh, {K. G.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/0022-4804(87)90175-2",
language = "English (US)",
volume = "42",
pages = "402--410",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Stimulation of neomucosal growth by systemic urogastrone

AU - Thompson, Jon S

AU - Sharp, John G

AU - Saxena, S. K.

AU - McCullagh, K. G.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Patching small intestinal defects with colon serosa results in the growth of functional neomucosa. However, the rate of neomucosal growth is slow and the defect contracts markedly. The aim of this study was to determine if systemic urogastrone would enhance neomucosal growth. Twenty-two New Zealand white rabbits had two 2 × 5-cm ileal defects patched with colon serosa and osmotic pumps placed subcutaneously. Eleven animals had saline infused at a rate of 5 μl/hr. The other eleven rabbits had urogastrone (1 mg/ml saline) infused at the same rate. One animal died in this group. There was a modest increase in neomucosal growth after 2 weeks of urogastrone infusion. Three weeks after patching, defect coverage was significantly greater in the urogastrone group (99.8 ± 0.1 vs 96.0 ± 1.2%, P < 0.005) and more defects were completely covered by neomucosa ( 6 10 vs 1 12, P < 0.05). Less contraction occurred in the urogastrone group (46 ± 2 vs 35 ± 3% initial defect, P < 0.005) and resultant neomucosal surface area was greater (361 ± 12 vs 266 ± 20 mm2, P < 0.0005). In vitro glucose uptake was significantly greater in the urogastrone group but disaccharidase and diamine oxidase activity were similar. Crypt cell production rate was significantly greater 2 weeks after operation compared to 3 weeks in both groups and was greater in the urogastrone group compared to the saline group at 2 weeks (24.9 ± 1.1 vs 20.1 ± 1.1, P < 0.02). Systemic urogastrone enhances neomucosal growth by increasing the rate of growth and diminishing contraction. A marked proliferative response is associated with intestinal patching prior to 21 days and is increased by systemic urogastrone.

AB - Patching small intestinal defects with colon serosa results in the growth of functional neomucosa. However, the rate of neomucosal growth is slow and the defect contracts markedly. The aim of this study was to determine if systemic urogastrone would enhance neomucosal growth. Twenty-two New Zealand white rabbits had two 2 × 5-cm ileal defects patched with colon serosa and osmotic pumps placed subcutaneously. Eleven animals had saline infused at a rate of 5 μl/hr. The other eleven rabbits had urogastrone (1 mg/ml saline) infused at the same rate. One animal died in this group. There was a modest increase in neomucosal growth after 2 weeks of urogastrone infusion. Three weeks after patching, defect coverage was significantly greater in the urogastrone group (99.8 ± 0.1 vs 96.0 ± 1.2%, P < 0.005) and more defects were completely covered by neomucosa ( 6 10 vs 1 12, P < 0.05). Less contraction occurred in the urogastrone group (46 ± 2 vs 35 ± 3% initial defect, P < 0.005) and resultant neomucosal surface area was greater (361 ± 12 vs 266 ± 20 mm2, P < 0.0005). In vitro glucose uptake was significantly greater in the urogastrone group but disaccharidase and diamine oxidase activity were similar. Crypt cell production rate was significantly greater 2 weeks after operation compared to 3 weeks in both groups and was greater in the urogastrone group compared to the saline group at 2 weeks (24.9 ± 1.1 vs 20.1 ± 1.1, P < 0.02). Systemic urogastrone enhances neomucosal growth by increasing the rate of growth and diminishing contraction. A marked proliferative response is associated with intestinal patching prior to 21 days and is increased by systemic urogastrone.

UR - http://www.scopus.com/inward/record.url?scp=0023219213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023219213&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(87)90175-2

DO - 10.1016/0022-4804(87)90175-2

M3 - Article

VL - 42

SP - 402

EP - 410

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 4

ER -